… In this systematic review and meta-analysis, all randomised trials comparing P2Y 12
inhibitor with aspirin monotherapy for secondary prevention in patients with cerebrovascular, …

… with currently recommended oral P2Y 12 inhibitors (clopidogrel, prasugrel, or ticagrelor) vs
aspirin monotherapy for the secondary prevention of adjudicated adverse events exclusively …

… In conclusion, in this meta-analysis of randomized trials, P2Y 12 inhibitor monotherapy for
chronic secondary prevention was associated with lower risk of MACE and MI compared with …

… for the secondary prevention and also duration of therapy. Herein, we aim to provide a
comprehensive review of the role of P2Y 12 receptor inhibitors in the secondary prevention of …

… This systematic review aimed to compare early use of P2Y12 inhibitors (clopidogrel/ticagrelor)
plus aspirin to aspirin alone for acute treatment and secondary prevention in acute non-…

… in the treatment and secondary prevention of atherosclerotic … strategy for long-term secondary
prevention, a field where … long-term secondary prevention of cardiovascular events in …

… Our meta-analysis showed that using P2Y 12 inhibitors for secondary prevention of ASCVD
events was associated with lower rates of myocardial infarction and stroke without any …

… controversial, more prolonged use of a P2Y 12 inhibitor on a background of aspirin reduces
risk of recurrent cardiac events in secondary prevention, but increases the risk of bleeding. …

… aspirin, P2Y12 inhibitors have been … P2Y12 inhibitors are stronger platelet inhibitors than
aspirin [10, 11]. Several trials comparing P2Y12 inhibitors with aspirin for secondary prevention …

… meta-analyses suggest that P2Y12 inhibitors are more effective and … P2Y12 inhibitors
should become the preferred single agent antiplatelet therapy for long-term secondary prevention…